Medical/Pharmaceuticals
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy
NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH...
2025-12-12 21:35
5775
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
* Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. * The partnership combines Insilico's generative AI ...
2025-12-12 20:00
4467
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study wi...
2025-12-12 10:31
5608
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
* After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior to those observed in the placebo group (BMI r...
2025-12-12 08:00
4478
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
Highlights: * FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol * This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial * Next steps include obtaining single IRB approval, site initiations and cl...
2025-12-12 04:49
5149
Datasea Announces Breakthrough in Acoustic-Driven Brain-Computer Interface Technology
Developing Healthcare and Intelligent Interaction Through Core Acoustic Innovation BEIJING, Dec. 11, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a global technology enterprise specializing in acoustic high-tech innovations and AI multimodal digital solutions, t...
2025-12-11 22:30
4132
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors TAIPEI, SHANGHAI, AND SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechn...
2025-12-11 21:00
6090
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
* Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseases * OTR Therapeut...
2025-12-11 14:00
2567
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment...
2025-12-11 09:53
3531
Samsung Biologics recognized as a global leader in water security
* Company receives the highest Water Security rating in two years into participation * Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 10, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing or...
2025-12-11 07:30
4142
DNV RECEIVES CMS APPROVAL FOR NEW AMBULATORY SURGERY CENTERS ACCREDITATION PROGRAM
New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 /PRNewswire/ -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory...
2025-12-10 22:32
6552
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters Reinvigoration of immune system + turning cold tumors hot Preliminary ex-vivo data in HER2+ patients demonstrates immune reinvigoration and reductions...
2025-12-10 21:00
7638
Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
2025-12-10 08:26
3112
Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore
* Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatments * Highlighted clinical value of Neurophet AQUA AD…To accelerate efforts across healthcare institutions inSoutheast Asia SEOUL, South...
2025-12-09 22:00
5892
Medit Launches AuraVue: A Unified 3D Intraoral Scan and X-Ray Visualization Powered by Overjet AI
NEWPORT BEACH, Calif., Dec. 9, 2025 /PRNewswire/ -- Medit, a global leader in 3D intraoral scanning and digital dentistry solutions, today announced the launch of AuraVue, a next-generation visualization and consultation platform that integrates Overjet's AI technology to deliver real-time diagno...
2025-12-09 21:30
3209
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into ...
2025-12-09 19:55
3068
Dimora Medical Recognized as Key Driver in Winner Medical's Amazon Award
NEW YORK, Dec. 9, 2025 /PRNewswire/ -- Winner Medical, the parent company of Dimora Medical, has been honored with the Paid Service Operation Excellence Award at the 2025 Amazon Global Selling Seller Conference, which focuses on excellence, innovation and global market. As one of Winner Medical's...
2025-12-09 18:35
3704
Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights includ...
2025-12-09 18:00
3323
Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025
HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen (oxaliplatin + tegafur/gimeracil/oteracil) as n...
2025-12-09 15:50
2659
GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy
YONGIN, South Korea, Dec. 9, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its study analyzing cell-free DNA (cfDNA) fragmentation patterns in 1,154 healthy individuals has been published in Clinical Chemistry (Impact Factor 6.3, 2025). The ...
2025-12-09 14:54
4467
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21Nuix Neo Generative AI Framework
[Picked up by 260 media titles]
2026-10-08 08:02Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
10781
LEIFRAS Co., Ltd. Reports First Half of Fiscal Year 2026 Financial Results
2026-10-08 09:50
8413
XPENG G9L Completes First Production Trial in Europe
2026-10-08 07:33
8051
